Brendan Magrab
Chief Executive Officer
Mr. Magrab has more than 20 years of experience in pharmaceutical development and marketing. He was most recently President of Transpharmative Advisors. Before that he was President and Chief Executive Officer of URL Pharma, Inc. where he had held positions of increasing responsibility, serving as Vice President of Intellectual Property, then General Counsel and then Executive Vice President of Commercial Operations. He was Vice President of Intellectual Property for Alpharma, Inc. and he served as an associate at a Washington D.C law firm, as a law clerk for the U.S. Court of Appeals for the Federal Circuit and as a Patent Examiner at the U.S. Patent and Trademark Office. He was elected Chairman of HedgePath Pharmaceuticals, Inc. in November 2016. Mr. Magrab received his Bachelors Degree in Biochemistry and Art History from the University of Virginia and his Juris Doctor from Georgetown University Law Center.
Chief Executive Officer
Mr. Magrab has more than 20 years of experience in pharmaceutical development and marketing. He was most recently President of Transpharmative Advisors. Before that he was President and Chief Executive Officer of URL Pharma, Inc. where he had held positions of increasing responsibility, serving as Vice President of Intellectual Property, then General Counsel and then Executive Vice President of Commercial Operations. He was Vice President of Intellectual Property for Alpharma, Inc. and he served as an associate at a Washington D.C law firm, as a law clerk for the U.S. Court of Appeals for the Federal Circuit and as a Patent Examiner at the U.S. Patent and Trademark Office. He was elected Chairman of HedgePath Pharmaceuticals, Inc. in November 2016. Mr. Magrab received his Bachelors Degree in Biochemistry and Art History from the University of Virginia and his Juris Doctor from Georgetown University Law Center.
A. Franklin Rice, M.B.A.
Chief Financial Officer
Mr. Rice is a 25-year veteran of the biotech industry and has held increasingly responsible positions in business development, finance, and senior management since 1989. During that time he has raised an aggregate of over $100 million in financings through the sale of equity and debt securities, and corporate development transactions including two mergers and acquisition, multiple strategic alliances and technology license transactions, and multiple awards of non-dilutive research funding. Mr. Rice was one of the first employees at VistaGen Therapeutics, Inc. (OTCBB: VSTA), one of the world’s first embryonic stem cell companies, during which time he held various management positions including Vice President of Business Development, Senior Vice President of Finance, and Chief Financial Officer, and oversaw the company’s Series A, B and C round private placements and its ‘going public’ transaction in 2011. Prior to VistaGen, Mr. Rice was Vice President of Pharmaceuticals and Biotechnology for Bechtel Group (San Francisco) and Senior Director of Business Development for Genencor International (Palo Alto, CA) following its successful spin-out from Genentech. Mr. Rice holds a bachelors degree in chemical engineering from Clarkson University, and business degrees from the Simon School of Business at the University of Rochester, and the Massachusetts Institute of Technology. He also serves on the board of directors of the Epilepsy Foundation of Northern California and is member of the the advisory board of the American Diabetes Association Silicon Valley Chapter.
Chief Financial Officer
Mr. Rice is a 25-year veteran of the biotech industry and has held increasingly responsible positions in business development, finance, and senior management since 1989. During that time he has raised an aggregate of over $100 million in financings through the sale of equity and debt securities, and corporate development transactions including two mergers and acquisition, multiple strategic alliances and technology license transactions, and multiple awards of non-dilutive research funding. Mr. Rice was one of the first employees at VistaGen Therapeutics, Inc. (OTCBB: VSTA), one of the world’s first embryonic stem cell companies, during which time he held various management positions including Vice President of Business Development, Senior Vice President of Finance, and Chief Financial Officer, and oversaw the company’s Series A, B and C round private placements and its ‘going public’ transaction in 2011. Prior to VistaGen, Mr. Rice was Vice President of Pharmaceuticals and Biotechnology for Bechtel Group (San Francisco) and Senior Director of Business Development for Genencor International (Palo Alto, CA) following its successful spin-out from Genentech. Mr. Rice holds a bachelors degree in chemical engineering from Clarkson University, and business degrees from the Simon School of Business at the University of Rochester, and the Massachusetts Institute of Technology. He also serves on the board of directors of the Epilepsy Foundation of Northern California and is member of the the advisory board of the American Diabetes Association Silicon Valley Chapter.
Jon S. Saxe
Director
Mr. Saxe has served as a director of over 25 companies and at present is a director of three public companies, Durect Corporation (NASDAQ: DRRX), VistaGen (NASDAQ:VTGN) and SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) and private companies Arbor Vita, Arcuo Medical, Armetheon, Cancer Prevention Pharmaceuticals, Lumos Pharma and Trellis Bioscience. He was President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) (NASDAQ: PDLI) from 1995 to 1999. In 1999-2000 he was E-I-R at Institutional Venture Partners. From 1993 to 1995, Mr. Saxe was Principal of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic and pharmaceutical companies. From 1989 to 1993 he was the President and CEO of Synergen, Inc., a biotechnology company purchased by Amgen. Prior to then Mr. Saxe was Vice President, Licensing and Corporate Development and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for 29 years. Mr. Saxe received a B.S.Ch,E. from Carnegie Mellon University, his J.D. from George Washington University School of Law, his LL.M. from New York University School of Law and a Certificate in Business Administration from Duke University.
Director
Mr. Saxe has served as a director of over 25 companies and at present is a director of three public companies, Durect Corporation (NASDAQ: DRRX), VistaGen (NASDAQ:VTGN) and SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) and private companies Arbor Vita, Arcuo Medical, Armetheon, Cancer Prevention Pharmaceuticals, Lumos Pharma and Trellis Bioscience. He was President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) (NASDAQ: PDLI) from 1995 to 1999. In 1999-2000 he was E-I-R at Institutional Venture Partners. From 1993 to 1995, Mr. Saxe was Principal of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic and pharmaceutical companies. From 1989 to 1993 he was the President and CEO of Synergen, Inc., a biotechnology company purchased by Amgen. Prior to then Mr. Saxe was Vice President, Licensing and Corporate Development and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for 29 years. Mr. Saxe received a B.S.Ch,E. from Carnegie Mellon University, his J.D. from George Washington University School of Law, his LL.M. from New York University School of Law and a Certificate in Business Administration from Duke University.
Randall B. Murphy, Ph.D.
Co-Founder and Director
Prior to co-founding Epalex, Dr. Murphy was senior vice-president at Medkura Pharmaceuticals, a pharmaceutical development company. From 1978-2000, Dr. Murphy was a tenured faculty member at New York University and an adjunct faculty member at Cornell University Medical College in chemistry, neuroscience, and biological psychiatry. Beginning in 2000, he became active as an entrepreneur in the biotechnology/biopharmaceuticals industry, having co-founded several companies, including Achillion Pharmaceuticals (Nasdaq: ACHN), which is now public, and Marinus Pharmaceuticals (Nasdaq: MRNS), a specialty pharmaceutical company focused on epilepsy which raised more than $70 million in venture financing and is now also a public company. Dr. Murphy is an expert in discovery medicinal chemistry and early to late-stage pharmaceutical development. He is the youngest graduate of the University of Southern California and is a recipient of the Presidential Fellowship from New York University. Dr. Murphy holds a Ph.D. in chemistry from the University of California, Los Angeles. He is the author of more than 180 research publications and is an inventor on 15 issued patents.
Co-Founder and Director
Prior to co-founding Epalex, Dr. Murphy was senior vice-president at Medkura Pharmaceuticals, a pharmaceutical development company. From 1978-2000, Dr. Murphy was a tenured faculty member at New York University and an adjunct faculty member at Cornell University Medical College in chemistry, neuroscience, and biological psychiatry. Beginning in 2000, he became active as an entrepreneur in the biotechnology/biopharmaceuticals industry, having co-founded several companies, including Achillion Pharmaceuticals (Nasdaq: ACHN), which is now public, and Marinus Pharmaceuticals (Nasdaq: MRNS), a specialty pharmaceutical company focused on epilepsy which raised more than $70 million in venture financing and is now also a public company. Dr. Murphy is an expert in discovery medicinal chemistry and early to late-stage pharmaceutical development. He is the youngest graduate of the University of Southern California and is a recipient of the Presidential Fellowship from New York University. Dr. Murphy holds a Ph.D. in chemistry from the University of California, Los Angeles. He is the author of more than 180 research publications and is an inventor on 15 issued patents.
